Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

This release includes forward-looking statements concerning the company's plans to initiate Phase III trials of the subcutaneous administration of GAMMAGARD LIQUID alone and with Enhanze Technology and expectations regarding the availability of the results related thereto. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: timely submission and approval of anticipated regulatory filings; the ability of the company to enroll a sufficient number of qualified participants in the proposed Phase III trials; the ability of the company to otherwise successfully initiate the Phase III trials; the ability of the company to complete the Phase III trials or any of them on a timely basis; and other risks discussed in the company's filings with the Securities and Exchange Commission (SEC) that could cause actual results to differ materially from those in the forward-looking statements. The company's SEC filings are available on its website. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changes assumptions or otherwise, and all forward- looking statements speak only as of the time when made. Actual results or experience could differ materially from the expectations contained in the forward-looking statements.

GAMMAGARD LIQUID and KIOVIG are trademarks of Baxter Hea
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Havel,s market leading EchoStim® Echogenic Insulated needle has ... Peripheral Nerve Blocks (PNBs) using nerve stimulation and ... improved needle has more, brighter, easier to see ... inexperienced practitioners the benefits of using both nerve ...
... 12, 2011 The association representing Montana,s providers of ... bill in Congress to repeal the controversial Medicare "competitive" ... "It is imperative that H.R. 1041 pass ... Medicare patients and local businesses in Montana," said Mike ...
Cached Medicine Technology:Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... Management Team and Board of Directors , ... Company,s VisionCHERRY HILL, N.J., March 18 eFoodSafety.com, Inc. ... company with a portfolio of aesthetic, dermatology, environmental and ... name from eFoodSafety.com, Inc. to Nuvilex, Inc. The Company ...
... software provider , is launching a new website. The website ... in-depth understanding of EMR-integrated services Also featured are an email ... , ... Little Rock, AR (PRWeb) March 18, 2009 ...
... EXTON, Pa., March 18 Kensey Nash Corporation (Nasdaq: ... has approved a stock repurchase. The new program allows ... of its issued and outstanding shares of Common Stock and ... the repurchases using its available cash. "Given our strong cash ...
... YORK, March 18 The Dirty Secrets ... products labeled "fragrance free" may actually contain chemicals to ... pollute the air in your home with harmful chemicals. ... about common spring cleaning hazards and how to avoid ...
... SAN FRANCISCO, March 18 The Women,s Dermatologic ... announces the 2009-2010 presidency of Wendy E. Roberts, ... Annual Meeting Luncheon held recently in conjunction with the ... Suzanne M. Connolly, MD , served as WDS ...
... Patient,s Own Stem Cells to Be Harvested and Transplanted ... Permanent Dental ImplantationRANCHO SANTA MARGARITA, Calif., March 18 ... infectious grin, but to attach an implant would be ... in his jaw. Dr. Ivan Ho, a Southern ...
Cached Medicine News:Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 2Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 3Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 4Health News:New Electronic Medical Transcription Company Website Arrives 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:Five Hot Show Ideas for Spring-Related Topics 2Health News:Wendy E. Roberts, MD, Named 2009-2010 President of the Women's Dermatologic Society 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 3
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy tubes ... removal of secretions from above the tracheostomy ... ULTRA® Suctionaid® tracheostomy tubes provide an additional ... from above the tracheostomy tube cuff helping ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
... For additional patient safety, the ... an integral 15 mm ISO ... to a ventilator, with or ... place , ,Portex® laryngectomy ...
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
Medicine Products: